Vertex Pharmaceuticals (NASDAQ:VRTX)

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

With 2017 coming to an end, investors are wondering how they should be investing for 2018 and beyond. At the start of December, the Dow was up just over 20% ...
Read Full Story »

Credit Suisse Issues 8 Top Number-One Picks for 2018

With less than 60 days until the end of 2017, firms are starting to issue preliminary predictions for 2018. These should not yet be considered formal lists for 2018 because, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: American Airlines, Boeing, Cabot Oil & Gas, Pandora, Southern Co., Vertex and Many More

Stocks were indicated to open higher yet again on Tuesday for all-time highs on the Dow and S&P 500. The one theme that has persisted through all the caution and ...
Read Full Story »

Wednesday’s Biggest Winners and Losers in the S&P 500

July 19, 2017: The S&P 500 closed up 0.5% at 2,473.50. The DJIA closed up 0.3% at 21,636.85. Separately, the Nasdaq closed up 0.6% at 6,385.04. Wednesday was a relatively ...
Read Full Story »

Vertex Wins Big in Mid-Stage Cystic Fibrosis Trial

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) saw its shares make an incredible gain on Wednesday after the company announced results from its early and mid-stage trials in cystic fibrosis (CF). The ...
Read Full Story »

Top Analyst Upgrades & Downgrades: Boeing, Chipotle, First Solar, Goldman Sachs, IBM, Lockheed Martin, Lululemon, Vertex and Many More

Stocks were indicated to open only slightly higher on Wednesday after a mixed bag of corporate earnings. What investors need to understand is that the major equity indexes remain just ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agilent, Apple, Citigroup, Exxon, M&T Bank, Snap, Toyota, Twitter and Many More

Stocks were marginally lower on Tuesday morning, but the major indexes all remain within striking distance of their all-time highs. Now that the bull market is over eight years old, ...
Read Full Story »

Analyst Predicts Major Short Squeeze in 4 Biotech Stocks to Buy

If any industry has done a head-spinning turnaround recently it was biotechnology. Last week saw the Nasdaq Biotech Index spike up almost 9%. While some was given back so far ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AK Steel, Altice USA, Biogen, Caterpillar, Gilead, Oracle and Many More

Stocks have recently hit all-time highs again, but the stock indexes seem to have gone sideways in recent days and they were looking for direction on a slow news Friday. ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Analog Devices, Camping World, Ciena, Deere, RSP Permian, Ulta Beauty, Yum China and Many More

Stocks were indicated to open higher on Friday at a record. This is after President Trump exited the Paris climate accord and after a weaker than expected nonfarm payrolls report. ...
Read Full Story »

Wednesday’s Biggest Winners and Losers in the S&P 500

May 31, 2017: The S&P 500 closed lower on the day, down 0.05% at 2,411.73. Separately the DJIA closed down 0.11% at 21,005.93. The Nasdaq also closed down 0.08% at ...
Read Full Story »

Hot Recent Tech IPO Highlights Jefferies Top Growth Stocks to Buy

The first quarter ended Friday, and despite the overall outstanding gains for the quarter, the gains were all in January and February as March was essentially flat. With earnings reporting starting ...
Read Full Story »

The 5 Best Performing S&P 500 Stocks for Q1

Between the November election and the end of 2016, the S&P 500 index gained 4.6%. Since the beginning of 2017, the index has added another 5.53%. The so-called Trump bump ...
Read Full Story »

Wednesday’s Biggest Winners and Losers in the S&P 500

March 29, 2017: The S&P 500 closed higher on the day, up 0.11 % and 2.56 points to 2,361.14. Separately the DJIA closed down 0.20% on the day at 20,659.39, ...
Read Full Story »

Why This Key Analyst Has a Mixed View of Vertex’s Win

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares jumped after the firm released results from two Phase 3 studies in the treatment of cystic fibrosis in ages 12 and older. Ultimately they ...
Read Full Story »